Jakarta, Indonesia, 3 January 2023 - MicroPort® has been granted a registration certificate by the Ministry of Health of the Republic of Indonesia for its independently developed Foxtrot™ NC PTCA Balloon Catheter.
The Foxtrot™ NC PTCA Balloon Catheter is a non-compliant rapid-exchange balloon catheter indicated for coronary artery balloon angioplasty. By assisting in the implantation of balloon stents, it can improve the result of myocardial perfusion scans. The distal tip of the catheter is equipped with a non-compliant balloon that inflates to the rated diameter and length at recommended pressures. Two radiopaque markers on the balloon allow intraoperative X-ray fluoroscopy to monitor its location in the body.
This product is used both for pre-dilation of endovascular lesions prior to stent implantation as well as for precise post-dilation of stents after their implantation. This assists in reducing stent edge effect and protecting healthy tissue. It not only features high burst pressure and low compliance, but also low profile after deflation. Additionally, it has excellent traceability, deliverability and pushability.
As a significant hub along the "Belt and Road," in recent years, Indonesia has seen a sharp increase in the market size of medical devices, particularly in the substantial growth in demand for cardiovascular therapy products. Prior to this, a number of other medical devices for cardiovascular intervention entered the Indonesian market, including the Firehawk® Rapamycin Target Eluting Coronary Stent System, Firebird2® Rapamycin-Eluting Coronary CoCr Stent System and Foxtrot Pro™ PTCA Balloon Catheter. These were well-received by patients and medical professionals for their exceptional product features and clinical performance.
Founded in Shanghai in 1998 on the belief that every person has the right to high quality medical treatments, MicroPort Scientific Corporation (“MicroPort®”, stock code: 00853.HK) is today a global medical devices company with over 12,000 employees worldwide. We provide solutions across twelve therapeutic areas, including orthopedics, cardiac rhythm management, electrophysiology and endovascular. At MicroPort®, we are breaking barriers and accelerating access to life-changing solutions with the purpose of prolonging and reshaping the lives of patients everywhere. Our therapeutic solutions are available in more than 100 countries and over 20,000 hospitals around the world, and today, a patient benefits from a MicroPort® solution every six seconds.
More information is available at www.microport.com.